Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6001 to 6015 of 7682 results

  1. NICE encourages further research into the use of innovative technologies for the management of severe acute respiratory failure, and may review this guidance on publication of further evidence.

    Recommendation ID IPG391/1 Question NICE encourages further research into the use of innovative technologies for the management of severe

    Research recommendation
    Published
    9 June 2015

  2. NICE encourages further research on subretinal prosthesis system for retinitis pigmentosa. Outcomes should include the impact on quality of life and activities of day-to-day living, and durability of implants. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG537/1 Question NICE encourages further research on subretinal prosthesis system for retinitis pigmentosa. Outcomes

    Research recommendation
    Published
    25 January 2016

  3. NICE encourages further research on transcranial magnetic stimulation (TMS) for treating and preventing migraine. Data should be collected for all patients not entered into controlled trials. Studies should describe clearly whether its use is for treatment or prevention. They should report details of patient selection and the dose and frequency of use. Outcome measures should include the number and severity of migraine episodes, and quality of life in both the short and long term. The development of any neurological disorders (such as epilepsy) in the short or longer term after starting treatment should be documented.

    Recommendation ID IPG477/1 Question NICE encourages further research on transcranial magnetic stimulation (TMS) for treating and preventing

    Research recommendation
    Published
    9 June 2015

  4. NICE encourages further research into the effects of uterine artery embolisation compared with other procedures to treat adenomyosis, particularly for patients wishing to maintain or improve their fertility.

    Recommendation ID IPG473/1 Question NICE encourages further research into the effects of uterine artery embolisation compared with other

    Research recommendation
    Published
    9 June 2015

  5. NICE encourages further research on insertion of an annular disc implant at lumbar discectomy, particularly comparative trials. All studies should report details of patient selection and recurrence rates.

    Recommendation ID IPG506/1 Question NICE encourages further research on insertion of an annular disc implant at lumbar discectomy, particularly

    Research recommendation
    Published
    9 June 2015

  6. NICE encourages further research on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. Studies should describe whether the procedure is used for treatment or prevention, and whether it is used for cluster headache or migraine. Clinicians should clearly document details of patient selection and the treatment regimen. Outcome measures should include changes in the number and severity of cluster headache or migraine episodes, medication use, quality of life in the short and long term, side effects, acceptability, and device  durability. NICE may update this guidance on publication of further evidence.

    Recommendation ID IPG552/1 Question NICE encourages further research on transcutaneous stimulation of the cervical branch of the vagus

    Research recommendation
    Published
    6 April 2016

  7. NICE encourages further research, preferably randomised controlled trials, into percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access. This should report details of patient selection, particularly about vascular anatomy, technique used, need for training, patency of the fistula and its subsequent ease of use, and quality of life.

    Recommendation ID IPG710/01 Question NICE encourages further research, preferably randomised controlled trials, into percutaneous endovascular

    Research recommendation
    Published
    5 November 2021

  8. NICE encourages research into endovascular stentgrafting of popliteal aneurysms and may review this procedure on publication of further evidence.

    Recommendation ID IPG390/1 Question NICE encourages research into endovascular stentgrafting of popliteal aneurysms and may review this

    Research recommendation
    Published
    9 June 2015

  9. NICE encourages the company, NHS England and treatment centres to collect more evidence, particularly on the longer-term benefits and costs of eliglustat and enzyme replacement therapy for treating type 1 Gaucher disease.

    Recommendation ID HST5/1 Question NICE encourages the company, NHS England and treatment centres to collect more evidence, particularly

    Research recommendation
    Published
    12 October 2018

  10. NICE encourages the peer-reviewed publication of all further research for percutaneous balloon valvuloplasty for fetal critical aortic stenosis. Further research could be in the form of controlled trials, analysis of registry data or other observational studies. It should address patient selection, timing of the intervention and the natural history of the disease.

    Recommendation ID IPG613/1 Question NICE encourages the peer-reviewed publication of all further research for percutaneous balloon valvuloplasty

    Research recommendation
    Published
    10 December 2018

  11. NICE highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.

    Recommendation ID TA220/1 Question NICE highlighted the importance of collecting further data within registries of patients receiving biological

    Research recommendation
    Published
    9 June 2015

  12. NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, was sensitive to whether the patient access scheme would be realised in clinical practice. The Committee agreed that it would be critical to generate evidence to support the following: - The proportion of people who become eligible for the patient access scheme, that is, that they remain on treatment beyond 26 cycles. - The benefit of lenalidomide after 26 cycles, that is the associated overall survival and health related quality of life for those who remain on treatment beyond 26 cycles.

    Recommendation ID TA322/1 Question NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low-

    Research recommendation
    Published
    9 June 2015

  13. NICE proposes that a clinical trial is needed to establish the relative effectiveness of mannitol compared with hypertonic saline.

    Recommendation ID TA266/1 Question NICE proposes that a clinical trial is needed to establish the relative effectiveness of mannitol compared

    Research recommendation
    Published
    9 June 2015

  14. NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine kinase inhibitors (afatinib, erlotinib and gefitinib) in EGFR mutation-positive locally advanced or metastatic NSCLC.

    Recommendation ID TA310/1 Question NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine

    Research recommendation
    Published
    9 June 2015

  15. NICE recommended further research into the clinical effectiveness of BCM – Body Composition Monitor-guided fluid management in people with chronic kidney disease having dialysis. It noted that the ongoing BISTRO study will assess the effect of the device in people aged 18 years or over having haemodialysis. Further research should collect clinical-outcome data in the following populations:- adults (aged 18 years and over) having peritoneal dialysis- babies, children and young people (aged under 18 years) having haemodialysis- babies, children and young people (aged under 18 years) having peritoneal dialysis.

    Recommendation ID DG29/1 Question NICE recommended further research into the clinical effectiveness of BCM – Body Composition Monitor-guided

    Research recommendation
    Published
    12 October 2018